Application of recombinant human TSH in the diagnostic protocol of differentiated thyroid carcinoma;Aplicación de la TSH humana recombinante en el protocolo diagnóstico del cáncer diferenciado de tiroides

Revista Espanola de Medicina Nuclear

Volumn 24, Issue 3, 2005, Pages 152-160

  Jimenez Hoyuela Garcia J M ^a   Garcia Almeida J M ^a   Delgado Garcia A ^a   Aguilar Fernandez I ^a   Martinez Del Valle Torres M D ^a   Ortega Lozano, S ^a   Rebollo Aguirre, A ^a   Mancha Doblas, I ^a   Pinzon Martin J L ^a   Picon Cesar M J ^a   Zamorano Vazquez D ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Differentiated thyroid carcinoma; Radioiodine scan; Recombinant human thyrotropin; Thyroglobulin

Indexed keywords

IODINE 131; RECOMBINANT HORMONE; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIFFERENTIATED THYROID CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; THYROID CARCINOMA; WHOLE BODY SCINTISCANNING;

EID: 20544444990     PISSN: 02126982     EISSN: None     Source Type: Journal    
DOI: 10.1157/13073786     Document Type: Article

References (31)

1. Alcazar V, Mondéjar BM, Del Val TL, De Icaya PM, Del Olmo D, Juansolo MA, et al. Tasa de incidencia y características del cancer de tiroides en un área de la zona sur de Madrid. Endocrinología. 2000;45:179-82.
2. Fahey TJ III, Reves TS, Delbridge L. increasing incidence and changing presentation of thyroid cancer over a 30-year period. Br J Surg. 1995;82:518-20.
3. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306.
4. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-63.
5. Schlumberger M, Pacini F. thyroid tumors. Paris: Ediciones Nucleon; 1999. p. 167-80.
6. Dow KH, Ferrell B, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid. 1997;7:613-9.
7. Melmed S, Harada A, Hershman JM, Krishnamurthy GT, Blahd WH. Neutralizing antibodies to bovine thyrotropin in immunized patients with thyroid cancer. JCEM. 1980;51:358-63.
8. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med. 1997;337:888-96.
9. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999; 84(11):3877-85.
10. Robbins, RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, et al. Preparation by recombinant human thyrotropin of thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:619-25.
11. Gomez Camarero P, Martinez Brocca MA, Rodriguez Rodriguez JR, Navarro González E, Tirado Hospital JL, González Duarte D, et al. La TSH humana recombinante en el seguimiento de pacientes con cáncer diferenciado de tiroides. Rev Esp Med Nucl. 2003;22(5):295-305.
12. Rodriguez Rodriguez JR. La TSH humana recombinante (rhTSH) en el control y seguimiento de los pacientes con cáncer diferenciado de tiroides: más cerca del objetivo. Rev Esp Med Nucl. 1999;18(6):401-7.
13. Pellegriti G, Scollo C, Regalbuto C, Attard M, Marozzi P, Vermiglio F. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels. Clin Endocrinol (Oxf). 2003;58(5): 556-61.
14. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab. 2002;87(4):1490-8.
15. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab. 2002;87:3242-7.
16. Franceschi M, Kusic Z, Franceschi D, Lukinak L, Roncevic S. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med. 1996;37:446-51.
17. Montella L, Caraglia M, Abbruzzese A, Soricelli A, Del Prete S, Squame G, et al. Molecular technology and the recombinant TSH have changed diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulin. Experimental and Molecular Imaging. 2004;36(3):268-73.
18. David A, Blotta A, Bondanelli M, Rossi R, Rod E, Braverman LE, et al. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. J Nucl Med. 2001;42(10):1470-5.
19. Schöder H, Yeung HWD. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Seminars in Nuclear Medicine. 2004;34(3):180-97.
20. Menzel C, Zaplatnikov K, Diehl M, Dobert N, Hamscho N, Grunwald F. The influence of thyroglobuline on functional imaging in differentiated thyroid cancer. Nucl Med Commun. 2004;25(3):239-43.
21. Petrich T, Borner AR, Otto D, Hofmann M, Knapp WH. Influence of rhTSH on [(18)F] fluorodeoxyglucose uptake by differentiates thyrois carcinoma. Eur J Nucl Med Mol Imaging. 2002; 29(5):641-7.
22. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2003;88(8):3668-73.
23. Torlontano M, Crocetti U, D'Aloiso L, Bonfitto N, Di Giorgio A, Modoni S, et al. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol. 2003;148(1):19-24.
24. Pacini F, Molinaro E, Lippa F, Castagna MG, Agate L, Cevarelli C, et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001; 86:5686-90.
25. Mariani G, Fedeghini M, Augeri C, Villa G, Taddei GZ, Scopinaro G, et al. Clinical experience with recombinant human thyrotropin (rhTSH) in the management of patients with differentiated thyroid cancer. Cancer Biother Radiophar. 2000;15(2):211-7.
26. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role if serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88(4):1433-41.
27. Pacini F. Follow-up of differentiated thyroid cancer. Eur J Nucl Med. 2002;29 Suppl. 2:S492-6.
28. McDougall IR, Wiegel RJ. Recombinant human thryrotropin in the management of thyroid cancer. Curr Opin Oncol. 2001; 13(1):39-43.
29. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol. 2004;150:105-12.
30. Cohen O, Dabhi S, Karasik A, Zila Zwas S. Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH. Eur J Endocrinol. 2004;150(3):285-90.
31. Halperin Rabinovich I. Utilidad de la TSH recombinante en el diagnóstico y tratamiento de las enfermedades tiroideas. Endocrinol Nutr. 2003;50(2):45-8.